Biofrontera - Heiße Turnaround-Spekulation (Seite 5690)
eröffnet am 08.09.09 12:28:32 von
neuester Beitrag 30.04.24 09:10:34 von
neuester Beitrag 30.04.24 09:10:34 von
Beiträge: 66.511
ID: 1.152.884
ID: 1.152.884
Aufrufe heute: 124
Gesamt: 8.233.585
Gesamt: 8.233.585
Aktive User: 0
ISIN: DE0006046113 · WKN: 604611
0,3360
EUR
-11,58 %
-0,0440 EUR
Letzter Kurs 30.04.24 Tradegate
Neuigkeiten
14.09.23 · IRW Press |
21.06.23 · IRW Press |
06.06.23 · IRW Press |
11.05.23 · IRW Press |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
5,0700 | +211,04 | |
1,2500 | +92,01 | |
0,8905 | +74,51 | |
3,3500 | +48,56 | |
1,2099 | +34,52 |
Wertpapier | Kurs | Perf. % |
---|---|---|
8,2200 | -13,47 | |
1,2029 | -14,15 | |
1,6100 | -15,26 | |
7,9300 | -15,91 | |
3,5000 | -26,24 |
Beitrag zu dieser Diskussion schreiben
Klingt für mich so, als ob man die Gebühr tatsächlich wieder zurück bekommt.
Dann hätte man über 10 Mio Cash
“Guidance to Industry: User Fee Waivers, Reductions,
and Refunds for Drug and Biological Products”
(OMB Control Number 0910-0693)
CHANGE REQUEST (83-C)
Date: March 23, 2015
In brief, we are proposing a non-substantive change to the estimated burden to include burden hours that have been previously approved for the Small Business Administration (SBA) under OMB control number 3245-0101, for requests of information from applicants who have submitted pending small business waiver requests to FDA for fees for human drug applications. By way of background, Section 736(d)(1)(D) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) directs the Secretary to waive certain fees for small businesses named as applicants in a human drug application. The guidance, among other things, outlines the process in which SBA would work with FDA to help determine whether an applicant meets the criteria for being a small business. The guidance states that SBA may contact the applicant directly in order to request certain types of information regarding its size status, and that the applicant should not send this information directly to FDA.
The supporting statement for 0910-0693 states the following:
The FDA works with the Small Business Administration (SBA), which makes the determinations on whether the applicant is a small business for purposes of user fee waivers. SBA asks the applicant to submit certain information. That submission of information to SBA is already approved by OMB under OMB control number 3245-0101.
However, in November 2014, SBA informed FDA that it would no longer conduct size determinations for small business user fee waivers for FDA. As a result, FDA has had to develop a process for conducting its own size determinations for small business fee waivers for human drug applications. As part of this process, FDA plans to send a letter to applicants who currently have pending small business waiver requests, and ask them to submit their supporting documentation directly to FDA instead of SBA. The burden on applicants would not increase; rather, we estimate that it will decrease from the 4 hours estimated by SBA on its Form 355, Application for Small Business Size Determination (OMB Control No. 3245-0101), to 2 hours, because we are asking that applicants submit fewer supporting documents to FDA than they would have otherwise submitted to SBA.
Because FDA is now conducting these size determinations for applicants who request a small business waiver for human drug applications, SBA can amend 3245-0101 to reflect the reduction in SBA’s collection hours. We understand that SBA plans to submit a revised burden estimate to 3245-0101 which will take into account the fact that SBA is no longer conducting size determinations for FDA.
There are currently 19 small business waiver requests that are pending review. FDA will be unable to evaluate these requests until it receives this supporting documentation from applicants. Many of these applicants are waiting to learn if their waiver requests are granted before submitting human drug applications, because the fee that would be waived is significant ($2.3 million for a human drug application submitted in FY 2015). Any additional delay could deter or prevent applicants from submitting applications, delaying or preventing market entry of new drug products.
In sum, we are proposing to add burden hours that have been previously approved for SBA under control number 3245-0101, for requests of information from applicants who have submitted pending small business waiver requests to FDA for fees for human drug applications . Furthermore, we estimate that the burden will decrease from 4 hours to 2 hours because we are asking that applicants submit fewer supporting documents to FDA than they would have otherwise submitted to SBA.
Dann hätte man über 10 Mio Cash
“Guidance to Industry: User Fee Waivers, Reductions,
and Refunds for Drug and Biological Products”
(OMB Control Number 0910-0693)
CHANGE REQUEST (83-C)
Date: March 23, 2015
In brief, we are proposing a non-substantive change to the estimated burden to include burden hours that have been previously approved for the Small Business Administration (SBA) under OMB control number 3245-0101, for requests of information from applicants who have submitted pending small business waiver requests to FDA for fees for human drug applications. By way of background, Section 736(d)(1)(D) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) directs the Secretary to waive certain fees for small businesses named as applicants in a human drug application. The guidance, among other things, outlines the process in which SBA would work with FDA to help determine whether an applicant meets the criteria for being a small business. The guidance states that SBA may contact the applicant directly in order to request certain types of information regarding its size status, and that the applicant should not send this information directly to FDA.
The supporting statement for 0910-0693 states the following:
The FDA works with the Small Business Administration (SBA), which makes the determinations on whether the applicant is a small business for purposes of user fee waivers. SBA asks the applicant to submit certain information. That submission of information to SBA is already approved by OMB under OMB control number 3245-0101.
However, in November 2014, SBA informed FDA that it would no longer conduct size determinations for small business user fee waivers for FDA. As a result, FDA has had to develop a process for conducting its own size determinations for small business fee waivers for human drug applications. As part of this process, FDA plans to send a letter to applicants who currently have pending small business waiver requests, and ask them to submit their supporting documentation directly to FDA instead of SBA. The burden on applicants would not increase; rather, we estimate that it will decrease from the 4 hours estimated by SBA on its Form 355, Application for Small Business Size Determination (OMB Control No. 3245-0101), to 2 hours, because we are asking that applicants submit fewer supporting documents to FDA than they would have otherwise submitted to SBA.
Because FDA is now conducting these size determinations for applicants who request a small business waiver for human drug applications, SBA can amend 3245-0101 to reflect the reduction in SBA’s collection hours. We understand that SBA plans to submit a revised burden estimate to 3245-0101 which will take into account the fact that SBA is no longer conducting size determinations for FDA.
There are currently 19 small business waiver requests that are pending review. FDA will be unable to evaluate these requests until it receives this supporting documentation from applicants. Many of these applicants are waiting to learn if their waiver requests are granted before submitting human drug applications, because the fee that would be waived is significant ($2.3 million for a human drug application submitted in FY 2015). Any additional delay could deter or prevent applicants from submitting applications, delaying or preventing market entry of new drug products.
In sum, we are proposing to add burden hours that have been previously approved for SBA under control number 3245-0101, for requests of information from applicants who have submitted pending small business waiver requests to FDA for fees for human drug applications . Furthermore, we estimate that the burden will decrease from 4 hours to 2 hours because we are asking that applicants submit fewer supporting documents to FDA than they would have otherwise submitted to SBA.
Antwort auf Beitrag Nr.: 49.769.685 von angoli77 am 13.05.15 09:46:35Ohne Handel geschmolzen
Iceberg drüfte etwa noch 56 T Stück haben ... heute morge standen rd. 72 T Stück auf der 2,30
Antwort auf Beitrag Nr.: 49.763.784 von Owehh am 12.05.15 14:49:15rd. 90 T Stück in einer 1 Cent Spanne gehandelt 2,29/2,30
Antwort auf Beitrag Nr.: 49.763.583 von angoli77 am 12.05.15 14:28:20Mal schaun wie viel derjenige morgen für seine Aktien haben will! Seit Wochen bedient irgendjemand an den 10er Schritten jeden der kaufen möchte…
wieviel will der Affe auf der 2,30 noch verkaufen , dreckiger Insti Iceberg
Antwort auf Beitrag Nr.: 49.762.443 von Schwabinho am 12.05.15 12:43:59ja die Hoffnung stirbt zuletzt ... einfach nur zum gruseln
Danke für die Infos angoli
Antwort auf Beitrag Nr.: 49.761.726 von angoli77 am 12.05.15 11:27:54Nach der Kapitalerhöhung werden manche die "neuen Aktien" vielleicht auch noch abstossen (kleiner Gewinn), jedoch sollte die Deckelung dann endlich ein Ende haben.
zu schnigge : erstmal grundsätzlich nur für institutionelle Anleger , meine bank kann dort in meinem auftrag handeln/vermitteln , allerdings nur unlimitiert , vor diesem Hintergrund keine alternative für kauf oder verkauf von BZR
gibt nur 2 Möglichkeiten
1. du zeichnest
2. lässt die BZR wertlos verfallen , dann werden diese für den angemeldeten Mehrbezug verwendet oder Investoren angeboten
wenn du nicht zeichnest, kann sich ein größerer Insti deine Stücke ( und evtl. auch alle anderen freien Stücke ) für 2,30 genehmigen , welche er in dieser Größenordnung nicht über die Börse kaufen könnte
ich denke der kurs wird bis 19.5. unter 2,30 bleiben , um möglichst viele stücke in die "Nichtzeichnung" zu bekommen
gibt nur 2 Möglichkeiten
1. du zeichnest
2. lässt die BZR wertlos verfallen , dann werden diese für den angemeldeten Mehrbezug verwendet oder Investoren angeboten
wenn du nicht zeichnest, kann sich ein größerer Insti deine Stücke ( und evtl. auch alle anderen freien Stücke ) für 2,30 genehmigen , welche er in dieser Größenordnung nicht über die Börse kaufen könnte
ich denke der kurs wird bis 19.5. unter 2,30 bleiben , um möglichst viele stücke in die "Nichtzeichnung" zu bekommen
14.09.23 · IRW Press · Biofrontera |
21.06.23 · IRW Press · Biofrontera |
06.06.23 · IRW Press · Biofrontera |
11.05.23 · IRW Press · Biofrontera |